| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Aug 10, 2021 | Kineta Announces Patent Issuance for U.S. Patent Covering Composition of Matter of KCP506, a Novel Non-opioid Therapy for Chronic Pain | |
| Jul 27, 2021 | Kineta Announces Successful Completion of Pre-IND Meeting with the FDA for KVA12.1 | |
| Jul 20, 2021 | Kineta and Samsung Biologics Announce Development and Manufacturing Agreement for Anti-VISTA Antibody Immunotherapy | Kineta to leverage Samsung Biologics' development and manufacturing expertise to advance KVA12.1 to IND
Samsung Biologics San Francisco R&D center and South Korea headquarters to offer a seamless, end-to-end CDMO service
INCHEON, South ... |
| Jun 1, 2021 | Kineta Raises $10M in Funding | Kineta, Inc., a Seattle, WA-based clinical stage biotechnology company focused on the development of novel immunotherapies in oncology, closed its $10 million financing round.
The round was led by Cheongbo Industrial Co., Ltd.
Proceeds from... |
| Jun 1, 2021 | Kineta Closes $10 Million Financing Round to Advance Anti-VISTA Immuno-oncology Program | |
| Mar 25, 2021 | Kineta Presents Clinical Study Results of LHF-535 at the International Conference on Antiviral Research (ICAR) | |
| Mar 3, 2021 | Kineta Presenting at Multiple Investor Conferences in March 2021 | |
| Dec 15, 2020 | Kineta Announces First Participant Dosed in Phase 1 Clinical Trial of KCP506, A Novel Non-Opioid for the Treatment of Chronic Pain | |
| Oct 8, 2020 | Kineta to Extend Research Collaboration with Genentech to Develop a Novel Non-Opioid | |
| May 5, 2020 | Adverum soars on early gene therapy data; BerGenBio raises €45.4M on the heels of Covid-19 move | → Another cut of positive interim data have lifted expectations that Adverum’s gene therapy that could give the anti-VEGF developers a run for their money in wet AMD. In a Phase I trial, investigators reported that... |
| Aug 6, 2019 | Kineta Raises $1.8M in Funding | Kineta, Inc., a Seattle, WA-based clinical stage biotechnology company focused on the development of novel immunotherapies in oncology, neuroscience and biodefense, secured $1.8m Translation Fund Award supplement from the Wellcome Trust.
Th... |
| May 3, 2019 | Revealed: GeekWire Awards 2019 winners crowned as we celebrate the best of Pacific Northwest tech | (GeekWire Photo / Taylor Soper)
The strength and success of the people and companies across the Pacific Northwest tech ecosystem was on full display Thursday night at the GeekWire Awards.
It was so much fun celebrating with more than 900 of... |
| Apr 16, 2018 | Kineta signs multi-million dollar collaboration with Genentech to develop non-opioid pain medication | (Bigstock Photo)
As the U.S. opioid epidemic rages on, the need for effective alternative pain medications is only becoming more acute.
Seattle-based biotechnology company Kineta has been working on a non-opioid pain treatment technology fo... |
| Feb 23, 2016 | Northwest angel investment collective Keiretsu doles out $43.5M in 2015 | Photo via Shutterstock.
The Keiretsu Forum Northwest announced today in a news release that its regional collective of angel investors poured $43.5 million into 57 companies this past year, making 2015 the biggest year for investments by th... |
| Mar 14, 2014 | Kineta Receives Investment from angelMD | Kineta, Inc., a Seattle, WA-based biotechnology company, received an investment from angelMD and its physician-led investor network.
The amount of the transaction was not disclosed.
Led by Charles Magness, PhD, Founder and CEO, Kineta has a... |
| Feb 5, 2013 | Former oil trader, Yankees part-owner invests in Kineta | Seattle-based biotech upstart Kineta announced a new investment partnership with RLB Holdings, a Connecticut-based investment firm that partially owns the New York Yankees and is managed by a former Glencore international oil trader.
Actual... |
| Jun 6, 2012 | Kineta, Playing for Bunt Singles, Builds a Biotech Company Without VC Bucks | Share Share on Facebook Share on Twitter LinkedIn Email Reprints
One of the best-financed biotech startups in Seattle of the last five years hasn’t raised a dime of traditional venture capital. If Kineta can show it delivers returns without... |
| May 8, 2012 | Kineta, UW receive biodefense grant to study ways to wipe out deadly viruses like Ebola | The University of Washington, University of Texas Medical Branch and Kineta — a Seattle biotechnology upstart — have received an $8.1 million grant from the National Institute of Allergy and Infectious Diseases to develop drugs to combat Eb... |
| Kineta Announces $3 Million Registered Direct Offering | Clinical-stage biotech company Kineta has announced a registered direct offering of more than 890,000 shares of common stock expected to generate $3 million in gross proceeds.
Orrick represented Kineta, which focuses on the development of n... |
| Kineta | “Kineta fills a void in the biopharmaceutical industry by efficiently advancing first-in-class novel immunotherapies from discovery to proof of concept.” |
